AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT02151981 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

421

Enrollment

INDUSTRY

Sponsor class

Conditions

Anticancer Treatment

Interventions

DRUG: Chemotherapy
DRUG: Cross-over to Osimertinib

Sponsor

AstraZeneca